Impulsivity in Patients with Parkinson’s Disease

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington (DC): American Psychiatric Press; 2013.10.1176/appi.books.9780890425596Search in Google Scholar

2. Moeller F, Barratt E, Dougherty D, Schmitz J, Swann A. Psychiatric aspects of impulsivity. Am J Psychiatry. 2001;158(11):1783-93.10.1176/appi.ajp.158.11.178311691682Search in Google Scholar

3. Grant JE, Levine L, Kim D, Potenza M. Impulse control disorders in adult psychiatric inpatients. Am J Psychiatry. 2005;162(11):2184-8.10.1176/appi.ajp.162.11.218416263865Search in Google Scholar

4. Hamilton KR, Mitchell MR, Wing VC, Balodis IM, Bickel WK, Fillmore M, et al. Choice impulsivity: Definitions, measurement issues, and clinical implications. Personal Disord. 2015;6(2):182-98.10.1037/per0000099453572625867841Search in Google Scholar

5. Giovannoni G, O’Sullivan JD, Turner K, Manson AJ, Lees AJ. Hedonistic homeostatic dysregulation in patients with Parkinson’s disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry. 2000;68(4):423-8.10.1136/jnnp.68.4.423173687510727476Search in Google Scholar

6. Evans AH, Katzenschlager R, Paviour D, O’Sullivan JD, Appel S, Lawrence AD, et al. Punding in Parkinson’s disease: its relation to the dopamine dysregulation syndrome. Mov Disord. 2004;19(4):397-405.10.1002/mds.2004515077237Search in Google Scholar

7. Weintraub D, David AS, Evans AH, Grant JE, Stacy M. Clinical spectrum of impulse control disorders in Parkinson’s disease. Mov Disord. 2015;30(2):121-7.10.1002/mds.2601625370355Search in Google Scholar

8. McElroy S, Keck P, Pope H, Smith J, Strakowski S. Compulsive buying: a report of 20 cases. J Clin Psychiatry. 1994;55(6):242-8.Search in Google Scholar

9. O’Sullivan SS, Djamshidian A, Evans AH, Loane CM, Lees AJ, Lawrence AD. Excessive hoarding in Parkinson’s disease. Mov Disord. 2010;25(8):1026-33.10.1002/mds.2301620131391Search in Google Scholar

10. Weintraub D, Koester J, Potenza M, Siderowf A, Stacy M, Voon V, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol. 2010;67(5):589-95.10.1001/archneurol.2010.6520457959Search in Google Scholar

11. Hare T, Camerer C, Rangel A. Self-control in decision-making involves modulation of the vmPFC valuation system. Science. 2009;324(5927):646-8.10.1126/science.116845019407204Search in Google Scholar

12. Robert G, Drapier D, Verin M, Millet B, Azulay JP, Blin O. Cognitive impulsivity in Parkinson’s disease patients: assessment and pathophysiology. Mov Disord. 2009;24(16):2316-27.10.1002/mds.2283619908312Search in Google Scholar

13. McClure S, Laibson D, Loewenstein G, Cohen J. Separate neural systems value immediate and delayed monetary rewards. Science. 2004;306(5695):503-7.10.1126/science.110090715486304Search in Google Scholar

14. Krain AM, Wilson AL, Arbuckle R, Castellanos FX, Milham MP. Distinct neural mechanisms of risk and ambiguity: a meta-analysis of decision-making. Neuroimage. 2006;32(1):477-84.10.1016/j.neuroimage.2006.02.04716632383Open DOISearch in Google Scholar

15. Ondo WG, Lai D. Predictors of impulsivity and reward seeking behavior with dopamine agonists. Parkinsonism Relat Disord. 2008;14(1):28-32.10.1016/j.parkreldis.2007.05.00617702628Search in Google Scholar

16. Frank M, Seeberger L, O’Reilly R. By carrot or by stick: cognitive reinforcement learning in Parkinsonism. Science. 2004;306(5703):1940-43.10.1126/science.110294115528409Search in Google Scholar

17. Cools R. Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson’s disease. Neurosci Biobehav Rev. 2006;30(1):1-23.10.1016/j.neubiorev.2005.03.02415935475Search in Google Scholar

18. Gerlach M, Double K, Arzberger T, Leblhuber L, Tatschner, Riederer R. Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum. J Neural Transm. 2003;110(10):1119-27.10.1007/s00702-003-0027-514523624Search in Google Scholar

19. Sokoloff P, Giros B, Martres P, Bouthenet Ml, Schwartz JC. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature. 1990;347(6289):146-51.10.1038/347146a01975644Search in Google Scholar

20. Pizzagalli D, Evins A, Schetter E, Frank M, Pajtas R, Santesso D, et al. Single dose of a dopamine agonist impairs reinforcement learning in humans: behavioral evidence from a laboratory-based measure of reward responsiveness. Psychopharmacology (Berl). 2008;196(2):221-32.10.1007/s00213-007-0957-y226863517909750Search in Google Scholar

21. Charles NE, Ryan SR, Bray BC, Mathias CW, Acheson A, Dougherty D. Altered developmental trajectories for impulsivity and sensation seeking among adolescent substance users. Addict Behav. 2016;(60):235-41.10.1016/j.addbeh.2016.04.016490473727174219Open DOISearch in Google Scholar

22. Davis C, Levitan R, Kaplan A, Carter J, Reid C, Curtis C, et al. Reward sensitivity and the D2 dopamine receptor gene: a case-control study of binge eating disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(3):620-8.10.1016/j.pnpbp.2007.09.024Search in Google Scholar

23. Bowirrat A, Oscar-Berman M. Relationship between dopaminergic neurotransmission, alcoholism, and Reward Deficiency syndrome. Am J Med Genet B Neuropsychiatr Genet. 2005;132B(1):29-37.10.1002/ajmg.b.30080Search in Google Scholar

24. Forbes E, Brown S, Kimak M, Ferrell R, Manuck S, Hariri A. Genetic variation in components of dopamine neurotransmission impacts ventral striatal reactivity associated with impulsivity. Mol Psychiatry. 2009;14(1):60-70.10.1038/sj.mp.4002086Search in Google Scholar

25. Zack M, Poulos CX. Amphetamine primes motivation to gamble and gambling-related semantic networks in problem gamblers. Neuropsychopharmacology. 2004;29(1):195-207.10.1038/sj.npp.1300333Open DOISearch in Google Scholar

26. Weintraub D, Stewart S, Shea JA, Lyons K, Pahwa R, Driver-Dunckley E, et al. Validation of the questionnaire for impulsive-compulsive disorders in Parkinson’s disease (QUIP). Mov Disord. 2009;24(10):1461-7.10.1002/mds.22571Search in Google Scholar

27. Cabrini S, Baratti M, Bonfa F, Cabri G, Uber E, Avanzi M. Preliminary evaluation of the DDS-PC inventory: a new tool to assess impulsive-compulsive behaviours associated to dopamine replacement therapy in Parkinson’s disease. Neurol Sci. 2009;30(4):307-13.10.1007/s10072-009-0101-3Open DOISearch in Google Scholar

28. Okai D, Askey-Jones S, Mack J, Martin A, Chaudhuri KR, Samuel M, et al. Parkinson’s Impulse-Control Scale for the severity rating of impulse-control behaviors in Parkinson’s Disease: a semistructured clinical assessment tool. Mov Disord Clin Pract. 2016;3(5):494-9.10.1002/mdc3.12316Search in Google Scholar

29. Patton JH, Stanford MS, Barratt ES. Factor structure of the Barratt impulsiveness scale. J Clin Psychol. 1995;51(6):768-74.10.1002/1097-4679(199511)51:6<768::AID-JCLP2270510607>3.0.CO;2-1Open DOISearch in Google Scholar

30. Cloninger RC, Przybeck TR, Svrakic DM, Wetzel RD. The temperament and character inventory (TCI): a guide to its development and use. Center for Psychobiology of Personality, Washington University; 1994.10.1037/t03902-000Search in Google Scholar

31. Pattij T, Vanderschuren L. The neuropharmacology of impulsive behaviour. Trends Pharmacol Sci. 2008;29(4):192-9.10.1016/j.tips.2008.01.002Open DOISearch in Google Scholar

32. Fineberg N, Chamberlain S, Goudriaan A, Potenza M. New developments in human neurocognition: clinical, genetic, and brain imaging correlates of impulsivity and compulsivity. CNS Spectr. 2014;19(1):69-89.10.1017/S1092852913000801411333524512640Open DOISearch in Google Scholar

33. Reynolds B. A review of delay-discounting research with humans: relations to drug use and gambling. Behav Pharmacol. 2006;17(8):651-67.10.1097/FBP.0b013e3280115f9917110792Search in Google Scholar

34. Driver-Dunckley E, Samanta J, Stacy M. Pathological gambling associated with dopamine agonist therapy in Parkinson’s disease. Neurology. 2003;61(3):422-3.10.1212/01.WNL.0000076478.45005.EC12913220Open DOISearch in Google Scholar

35. Dodd ML, Klos KJ, Bower JH, Geda YE, Josephs KA, Ahlskog JE. Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol. 2005;62(9):1377-81.10.1001/archneur.62.9.noc5000916009751Search in Google Scholar

36. Sevincok L, Akoglu A, Akyol A. Quetiapine in a case with Parkinson disease and pathological gambling. J Clin Psychopharm. 2007;27(1):106-7.10.1097/JCP.0b013e31802e98c317224732Open DOISearch in Google Scholar

37. Hardwick A, Ward H, Hassan A, Romrell J, Okun M. Clozapine as a potential treatment for refractory impulsive, compulsive, and punding behaviors in Parkinson’s disease. Neurocase. 2013;19(6):587-91.10.1080/13554794.2012.71349022934916Open DOISearch in Google Scholar

38. Cooney JW, Stacy M. Neuropsychiatric issues in Parkinsons disease. Curr Neurol Neurosci Rep. 2016;16(5):49.10.1007/s11910-016-0647-427048443Open DOISearch in Google Scholar